Dr Stephen Lane, QIMR, QLD, 2011 GIA recipient
In 2011, the Leukaemia Foundation is investing $4.3 million in research projects nationally. This includes 7 new PhDs, 3 Fellowships, 17 Grants-in-Aid and a Clinical Trial grant.
The Leukaemia Foundation collaborates with various external organisations to fund vital research into the causes, epidemiology, diagnosis and treatment, psychosocial impact and ultimately cures for leukaemias, lymphomas, myeloma and related blood disorders.
Professor Ken Bradstock, Chair of the MSAC
The Medical and Scientific Advisory Committee (MSAC) was established in 2000 to provide strategic advice to the Leukaemia Foundation on medical, scientific, research and clinical matters. Members of the MSAC are drawn from the Australian scientific and medical research community and are each highly regarded in their fields of expertise.
The Leukaemia Foundation funds vital research into the causes, epidemiology, diagnosis and treatment, psychosocial impact and ultimately cures for leukaemias, lymphomas, myeloma and related blood disorders.
The University of Melbourne,
VIC, 2011 PhD recipient
The Leukaemia Foundation's vision is to help find better treatments and cures for the 45,000 Australians who will be diagnosed with leukaemia, lymphoma, and myeloma and related blood cancers and disorders in the next 5 years. For this reason, the Foundation annually invests at least $3.1 million into research.
Dr Andrew Wei, The Alfred Hospital, VIC, 2011 Clinical Trial Grant Recipient
The National Research Program seeks to foster innovative research into the causes, diagnosis and treatment of blood cancers like leukaemia, lymphoma, myeloma and related blood disorders. The program includes grants-in-aid to provide seed funding for novel research projects, whilst our fellowships and scholarships program aims to encourage talented young scientists, medical graduates and researchers to pursue a career in basic, applied or translational research to find cures and better ways to care for patients and families living with haematological malignancies.